Brief: AIM ImmunoTech Provides Update on Ampligen Long COVID Development Program
18/05/2022 13:43
May 18 (Reuters) - AIM ImmunoTech Inc AIM.A :
* AIM IMMUNOTECH PROVIDES UPDATE ON AMPLIGEN LONG COVID
DEVELOPMENT PROGRAM
* AIM IMMUNOTECH INC- WORKING TOWARD FILING AN IND
APPLICATION
WITH U.S. FDA FOR PHASE 2 STUDY OF AMPLIGEN FOR TREATMENT OF
POST-COVID CONDITIONS
* AIM IMMUNOTECH INC- NEWLY PLANNED IND IS FOR 12 WEEKS OF
THERAPY
Source text for Eikon: ID:nGNX14KqfZ
Further company coverage: AIM.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on AIM ImmunoTech
See all newsBrief: Aim Immunotech Duripanc Primary Endpoint Analysis To Begin December 2026 Topline Results Expected Q1 2027
Brief: Aim Immunotech Files To Offer And Resell Up To 13.08 Million Shares Of Common Stock By Selling Stockholders
Brief: AIM ImmunoTech Announces $2.65 Million Financing Priced At-Market Under NYSE American Rules
Brief: Aim Immunotech Announces Significant Increase In Stockholder Equity And Extension Of Promissory Note Maturity Date To June 2027
Brief: Aim Immunotech Announces 50% Objective Response Rate (Orr) In Upmc Recurrent Ovarian Cancer Phase 2 Clinical Trial, Suggesting Breakthrough Combination Potential